Pharmaceuticals companies continue to weigh options for their role in Accountable Care Organizations (ACOs).
Pharmaceuticals companies continue to weigh options for their role in Accountable Care Organizations (ACOs). As with other collaborators, they are deliberating ways they can best reduce costs and improve quality. MedCity News reports:
Like Will Rogers, Dr. David Nash is reluctant to predict the future. But when prodded, the dean of Jefferson’s School of Population Health described a post Accountable Care Act world in which pharmaceutical options will be dictated by outcomes and value. Pharmaceutical companies are trying to figure out the best way they can reduce costs and generate revenue.
“We’re going to see more emphasis on the cost effectiveness and cost benefit of products. Clearly any provider organization that’s going at economic risk…will care a lot more in 2015, 2016 about the economics of the pharma products they are using..We are in need of better population based data.”
The panel discussion at the CONVERGE conference in Philadelphia this week highlighted some interesting ways pharmaceutical companies can respond to these needs by Accountable Care Organizations and what else they can do to add value.
Read the full story: http://bit.ly/14KUjrI